A clinical study comparing treatment with Iberdomide, Daratumumab, and Dexamethasone to treatment with Daratumumab, Bortezomib, and Dexamethasone in patients with a refractory or progressing blood cancer called Multiple Myeloma (RRMM) (EXCALIBER-RRMM)
Résumé de l'étude
The aim of this study is to compare the efficacy of a new investigational drug, Iberdomide (CC-220) in combination with Daratumumab and Dexamethasone (IberDd) for the treatment of relapsed or refractory Multiple Myeloma with that of Daratumumab, Bortezomib, and Dexamethasone. In this study, the safety and efficacy of the Iberdomide combination will be tested against the other combination in a large number of patients, and it will be examined how patients feel about their treatment for Multiple Myeloma and how their health-related quality of life is. Approximately 864 participants will take part in this study worldwide. In Switzerland, about 6 participants will take part in the study at 2 centers. The expected duration of the study is as long as the disease does not worsen and as long as the patients tolerate the study treatment.
(BASEC)
Intervention étudiée
In Phase 1 of the study, at least 200 participants with RRMM will be randomized 1:1:1:1 to treatment arms A1, A2, A3 (IberDd) and treatment arm B (DVd). In Phase 2 of the study, approximately 664 participants with RRMM will be randomized 1:1 between treatment arm A (IberDd) and treatment arm B (DVd). Phase 1 treatment arms A1, A2, A3 and Phase 2 treatment arm A (IberDd) will receive treatment with Iberdomide, Daratumumab, and Dexamethasone: Iberdomide capsules will be taken at home on days 1-21 of each 28-day cycle. Dexamethasone tablets will be taken at home. The dose and dosing schedule depend on age, weight, and/or medical history. Daratumumab will be injected subcutaneously in the clinic. The frequency of Daratumumab administration depends on the treatment cycle the patient is in. Treatment arm A (DVd) will receive treatment with Daratumumab, Bortezomib, and Dexamethasone: Daratumumab subcutaneously (injection) in the clinic. The frequency of Daratumumab administration depends on the treatment cycle the patient is in. Bortezomib will be injected subcutaneously in the clinic until the end of cycle 7. The dose of Bortezomib depends on weight and height, which will be monitored regularly. Dexamethasone tablets will be taken at home. The dose and dosing schedule depend on age, weight, and/or medical history.
(BASEC)
Maladie en cours d'investigation
Multiple Myeloma, a cancer of plasma cells (a type of immune cell that produces antibodies) from the bone marrow, which has either returned after the last treatment (relapsed) or has not responded to the last treatment (refractory).
(BASEC)
The main inclusion criteria are: - documented diagnosis of MM and measurable disease - prior receipt of 1 to 2 prior cycles of anti-myeloma therapy - achieved response (partial response [PR] or better) to at least 1 prior anti-myeloma therapy. (BASEC)
Critères d'exclusion
The main exclusion criteria are: - infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within 14 days for mild or asymptomatic infection or within 28 days for severe/critical illness - certain laboratory abnormalities, e.g., in blood counts, liver values, or kidney values - peripheral neuropathy grade 3, grade 4, or grade 2 with pain (BASEC)
Lieu de l’étude
Chur, St-Gall
(BASEC)
Sponsor
Celgene Corporation
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
David Walter Pignolet
+41 32729 x8526
David.Pignolet@clutterbms.comCELGENE
(BASEC)
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Ethikkommission Ostschweiz EKOS
(BASEC)
Date d'approbation du comité d'éthique
08.04.2022
(BASEC)
Identifiant de l'essai ICTRP
NCT04975997 (ICTRP)
Titre officiel (approuvé par le comité d'éthique)
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING IBERDOMIDE, DARATUMUMAB AND DEXAMETHASONE (IberDd) VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (DVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) (EXCALIBER-RRMM) (BASEC)
Titre académique
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) (ICTRP)
Titre public
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ICTRP)
Maladie en cours d'investigation
Multiple Myeloma (ICTRP)
Intervention étudiée
Drug: DexamethasoneDrug: DaratumumabDrug: BortezomibDrug: IberdomideDrug: IberdomideDrug: IberdomideDrug: DexamethasoneDrug: Daratumumab (ICTRP)
Type d'essai
Interventional (ICTRP)
Plan de l'étude
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). (ICTRP)
Critères d'inclusion/exclusion
Inclusion Criteria
- Documented diagnosis of multiple myeloma (MM) and measurable disease.
- Received 1 to 2 prior lines of anti-myeloma therapy.
- Must have documented disease progression during or after their last anti-myeloma
regimen.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.
Exclusion Criteria
- Any condition that confounds the ability to interpret data from the study.
- Has plasma cell leukemia, Waldenstrom's macroglobulinemia or POEMS syndrome
(polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin
changes), or clinically significant amyloidosis.
- Known central nervous system involvement with MM.
- Prior therapy with iberdomide.
- Other protocol-defined Inclusion/Exclusion criteria apply. (ICTRP)
non disponible
Critères d'évaluation principaux et secondaires
Progression-free Survival (PFS);Minimal Residual Disease (MRD) negative Complete Response (CR) at any time (ICTRP)
Overall Survival (OS);Sustainability of Minimal Residual Disease (MRD) negativity;Overall Response Rate (ORR);Time to response (TTR);Duration of Response (DoR);Time to Progression (TTP);Time to Next Treatment (TTNT);Progression-free Survival 2 (PFS2);Safety;European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30);European Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20);Recommended iberdomide dose for Stage 2;Area under the plasma concentration-time curve from time zero to tau (AUC(TAU));Maximum plasma concentration (Cmax);Time to maximum plasma concentration (Tmax) (ICTRP)
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
Bristol-Myers Squibb;BMS Clinical Trials Contact Center www.BMSClinicalTrials.com, Clinical.Trials@bms.com, 855-907-3286, Bristol-Myers Squibb, (ICTRP)
ID secondaires
U1111-1260-2872, 2020-000431-49, CC-220-MM-002 (ICTRP)
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
https://clinicaltrials.gov/ct2/show/NCT04975997 (ICTRP)
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible